
Multiple Myeloma
Latest News
Video Series

Latest Videos
Shorts



Podcasts
More News

Surbhi Sidana, MD, discusses how the FDA-approved oral CELMoD iberdomide expands access and impacts nursing care in multiple myeloma.

Oncology clinical trial nurse navigator Elise Curry, RN, breaks down the key clinical questions surrounding the FDA approval of oral iberdomide.

The FDA granted accelerated approval to iberdomide with daratumumab and dexamethasone for relapsed/refractory multiple myeloma.

Duke Blood Cancer Center's Melissa LaMirand, FNP-C, discusses quad therapies, bispecific workflows, and nursing standardization in multiple myeloma.

Kevin Brigle, PhD, ANP, discusses frontline quads, managing toxicities of bispecifics, and the evolving role of nursing in multiple myeloma treatment.

Czarina Cecilio, BSN, RN, shares roundtable insights on toxicity management, injection techniques, and the critical role of nursing education.

FDA approves subcutaneous isatuximab-irfc for multiple myeloma indications, offering an efficient delivery alternative to intravenous administration.

A European survey at EHA 2026 finds nurses central to multiple myeloma care but facing training gaps and severe shortages that limit patient outcomes.

Phase 3 MagnetisMM-5 trial data in multiple myeloma highlight progression-free survival gains and key safety considerations for oncology nurses.

Oncology nurse practitioners discuss CD38-based frontline therapy for newly diagnosed multiple myeloma, including Dara-VRd efficacy, AE management, and subcutaneous administration strategies.

Natalia Neparidze, MD, discusses subcutaneous daratumumab safety, MRD as a clinical endpoint, and emerging therapies for multiple myeloma management.

Samantha Shenoy, NP, MSN, provides nursing guidance on teclistamab/subcutaneous daratumumab’s second-line approval in multiple myeloma.

Teclistamab plus daratumumab hyaluronidase-fihj has been approved for patients with relapsed/refractory multiple myeloma as part of the CNPV program.

FDA fast-tracks trispecific IBI3003, reviews iberdomide combo, and expands Yescarta use.

The FDA approved subcutaneous daratumumab/VRd in patients with newly diagnosed multiple myeloma who are not eligible for ASCT. Here’s what you should know.

Subcutaneous daratumumab plus teclistamab improved survival outcomes in patients with R/R multiple myeloma vs standard daratumumab-based regimens.




























































































